Literature DB >> 14529658

Ovarian cancer and high-risk women-implications for prevention, screening, and early detection.

Francesmary Modugno1.   

Abstract

OBJECTIVE: The aim of this study was to understand the strengths and limitations of current prevention, detection, and screening methods for ovarian cancer and to identify research areas to improve prevention, screening, and detection of the disease for all women as well as for women carrying a mutation in the BRCA1/2 genes.
METHODS: We convened an ovarian cancer symposium at the University of Pittsburgh in May 2002. Nineteen leading scientists representing disciplines such as epidemiology, molecular biology, pathology, genetics, bioinformatics, and psychology presented the latest data on ovarian cancer prevention, screening, and early detection.
RESULTS: Ovarian cancer is the most common cause of death from a gynecologic malignancy in the United States. Because survival depends on stage of diagnosis, early detection is critical in improving clinical outcome. However, existing screening techniques (CA125, transvaginal ultrasound) have not been shown to reduce morbidity or mortality. Moreover, with the exception of oral contraceptives, there are no available chemopreventive agents. Bilateral salpingo-oophorectomy also has been shown to reduce incidence, but this procedure has several drawbacks in terms of a woman's reproductive, cardiovascular, skeletal, and mental health.
CONCLUSIONS: Better methods to prevent, detect, and screen for ovarian cancer in all women, but particularly in high-risk women carrying mutations in BRCA1/2, are urgently needed. This article reviews the current state of knowledge in the etiology, prevention, and early detection of ovarian cancer and suggests several areas for future clinical, epidemiologic, and laboratory-based research.

Entities:  

Mesh:

Year:  2003        PMID: 14529658     DOI: 10.1016/s0090-8258(03)00254-3

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  11 in total

1.  Ovarian cancer: prevention, detection, and treatment of the disease and its recurrence. Molecular mechanisms and personalized medicine meeting report.

Authors:  Francesmary Modugno; Robert P Edwards
Journal:  Int J Gynecol Cancer       Date:  2012-10       Impact factor: 3.437

2.  Development and evaluation of a decision aid for BRCA carriers with breast cancer.

Authors:  Julie O Culver; Deborah J MacDonald; Andrea A Thornton; Sharon R Sand; Marcia Grant; Deborah J Bowen; Harry Burke; Nellie Garcia; Kelly A Metcalfe; Jeffrey N Weitzel
Journal:  J Genet Couns       Date:  2011-03-03       Impact factor: 2.537

Review 3.  Epidemiological and genetic factors associated with ovarian cancer.

Authors:  Monica R McLemore; Christine Miaskowski; Bradley E Aouizerat; Lee-May Chen; Marylin J Dodd
Journal:  Cancer Nurs       Date:  2009 Jul-Aug       Impact factor: 2.592

Review 4.  Ovarian cancer in endometriosis: epidemiology, natural history, and clinical diagnosis.

Authors:  Hiroshi Kobayashi
Journal:  Int J Clin Oncol       Date:  2009-10-25       Impact factor: 3.402

5.  Autologous immune enhancement therapy in recurrent ovarian cancer with metastases: a case report.

Authors:  Sadananda Rao Manjunath; Ganapathi Ramanan; Vidyasagar Devaprasad Dedeepiya; Hiroshi Terunuma; Xuewen Deng; Subramani Baskar; Rajappa Senthilkumar; Paramasivam Thamaraikannan; Thangavelu Srinivasan; Senthilkumar Preethy; Samuel J K Abraham
Journal:  Case Rep Oncol       Date:  2012-03-16

6.  Human papillomavirus genotyping and integration in ovarian cancer Saudi patients.

Authors:  Othman A Al-Shabanah; Mohamed M Hafez; Zeinab K Hassan; Mohamed M Sayed-Ahmed; Waleed N Abozeed; Salem S Al-Rejaie; Abdulmalik A Alsheikh
Journal:  Virol J       Date:  2013-11-20       Impact factor: 4.099

Review 7.  Protective Effect of Progesterone during Pregnancy against Ovarian Cancer.

Authors:  Kyung Hee Han; Mi-Kyung Kim; Hee Seung Kim; Hyun Hoon Chung; Yong Sang Song
Journal:  J Cancer Prev       Date:  2013-06

8.  The association of polymorphisms in nucleotide excision repair genes with ovarian cancer susceptibility.

Authors:  Zhiguang Zhao; Anqi Zhang; Yuan Zhao; Junmiao Xiang; Danyang Yu; Zongwen Liang; Chaoyi Xu; Qiong Zhang; Jianmin Li; Ping Duan
Journal:  Biosci Rep       Date:  2018-06-21       Impact factor: 3.840

9.  Overexpression of centromere protein K (CENPK) in ovarian cancer is correlated with poor patient survival and associated with predictive and prognostic relevance.

Authors:  Chi-Chen Huang; Ding-Yen Lin; Yi-Chao Lee; Wen-Chang Chang; Kuen-Haur Lee
Journal:  PeerJ       Date:  2015-11-05       Impact factor: 2.984

10.  No association between TP53 Arg72Pro polymorphism and ovarian cancer risk: evidence from 10113 subjects.

Authors:  Anqi Zhang; Ting-Yan Shi; Yuan Zhao; Junmiao Xiang; Danyang Yu; Zongwen Liang; Chaoyi Xu; Qiong Zhang; Yue Hu; Danhan Wang; Jing He; Ping Duan
Journal:  Oncotarget       Date:  2017-11-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.